<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387435</url>
  </required_header>
  <id_info>
    <org_study_id>19-002279</org_study_id>
    <secondary_id>OT2OD028201</secondary_id>
    <nct_id>NCT04387435</nct_id>
  </id_info>
  <brief_title>Optimization of VNS in Epileptic Patients to Induce Cardioprotection</brief_title>
  <official_title>A Feasibility Study to Evaluate the Safety and Effect of the Optimization of Vagus Nerve Stimulation in Epileptic Patients to Induce Cardioprotection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a non-randomized, prospective study in patients with a diagnosis of epilepsy&#xD;
      and previously implanted FDA approved Vagus Nerve Stimulation (VNS) devices. The goal of this&#xD;
      clinical investigation is to evaluate the effects of adjusting vagus nerve stimulation&#xD;
      parameters to engage cardioprotective effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy patients are at increased risk for sudden cardiac death. Mechanisms behind this&#xD;
      predisposition is poorly understood but parasympathetic dysfunction is heavily implicated.&#xD;
      Vagus Nerve Stimulation (VNS) protocols currently set for seizure management are poorly&#xD;
      optimized for cardioprotection, therefore this patient population presents a unique&#xD;
      opportunity to assess VNS control of cardiac function, when VNS is appropriately titrated for&#xD;
      cardiac and seizure benefit.&#xD;
&#xD;
      This study will enroll 12 patients with a diagnosis of epilepsy and previously implanted FDA&#xD;
      approved VNS devices. The study will last up to 9 weeks and the patient will undergo changes&#xD;
      to their VNS settings during autonomic testing and cardiopulmonary testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in seizure frequency or duration via a routine seizure history used in clinical practice.</measure>
    <time_frame>Following the 4 - week VNS treatment phase to the of the end of study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate and blood pressure in response to upright tilt, deep breathing, Valsalva maneuver and a cold pressor test.</measure>
    <time_frame>From pre VNS setting changes (baseline) to post VNS setting changes (end of study).</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Epilepsy</condition>
  <condition>Sudden Cardiac Death</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A change or titration in the current or frequency settings of the VNS therapy system.</intervention_name>
    <description>The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of refractory epilepsy and implanted with a VNS device or are&#xD;
             scheduled to be implanted with a VNS device.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Subjects must demonstrate willingness and ability to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other implantable neuromodulatory device (e.g., brain stimulator)&#xD;
&#xD;
          -  Treatment with cholinergic or anticholinergic medication in the past month&#xD;
&#xD;
          -  Pre-existing cardiac arrhythmia or presence of cardiac pacemaker/defibrillator&#xD;
&#xD;
          -  History of dysautonomias&#xD;
&#xD;
          -  History of vasovagal syncope&#xD;
&#xD;
          -  Progressive neurological diseases other than epilepsy&#xD;
&#xD;
          -  Women that are pregnant&#xD;
&#xD;
          -  Cognitive or psychiatric deficit that in the investigator's judgment would interfere&#xD;
             with the subject's ability to accurately complete study assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inna Keselman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie M Sorg, MSN</last_name>
    <phone>310-206-2235</phone>
    <email>jsorg@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olujimi Ajijola, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Keselman, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olujimi Ajijola, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Ardell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Bradfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalyanam Shivkumar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marmar Vaseghi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Inna Keselman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vagus Nerve Stimulation (VNS)</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Autonomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

